布瑞拉沙秦
布瑞拉沙秦 性质
| 沸点 | 643.0±55.0 °C(Predicted) |
|---|---|
| 密度 | 1.301±0.06 g/cm3(Predicted) |
| 储存条件 | 4°C, protect from light |
| 溶解度 | DMSO：100 mg/mL（222.04 mM；需要超声波） |
| 酸度系数(pKa) | 12.36±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | 米白色至浅黄色 |
| InChI | InChI=1S/C22H25Cl2N3O3/c23-17-4-3-5-19(22(17)24)27-11-9-26(10-12-27)8-1-2-13-29-16-6-7-20-18(14-16)25-21(28)15-30-20/h3-7,14H,1-2,8-13,15H2,(H,25,28) |
| InChIKey | PMKMNTBZJOXTJW-UHFFFAOYSA-N |
| SMILES | O1C2=CC=C(OCCCCN3CCN(C4=CC=CC(Cl)=C4Cl)CC3)C=C2NC(=O)C1 |
布瑞拉沙秦 用途与合成方法
|
5-HT 1A Receptor 1.5 nM (Ki) |
5-HT 2A Receptor 2.5 nM (Ki) |
5-HT 2B Receptor 0.19 nM (Ki) |
5-HT 7 Receptor 2.7 nM (Ki) |
D 2 Receptor
|
D 3 Receptor
|
D 4 Receptor
|
Brilaroxazine (oral gavage; 10 mg/kg; twice daily; 28 days) limits the functional and structural effects of pulmonary arterial hypertension (PAH), with significant improvements in pulmonary hemodynamics, right ventricular (RV) hypertrophy, SO2, and pulmonary blood vessel structural changes.
| Animal Model: | SD-rats |
| Dosage: | 10 mg/kg |
| Administration: | Oral gavage; twice daily; 28 days |
| Result: | Had the efficacy in PAH, and mitigated the functional and structural effects of MCT-induced PAH. |
布瑞拉沙秦 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-06-05 | HY-109112 | 1239729-06-6 | 1 mg | 1350 | |
| 2026-06-05 | HY-109112R | 布瑞拉沙秦 | 1239729-06-6 | 1 mg | 2900 |
